Orbimed Advisors Llc - Jan 14, 2022 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Role
10%+ Owner
Signature
/s/ Carl Gordon, Member of OrbiMed Advisors LLC
Stock symbol
PASG
Transactions as of
Jan 14, 2022
Transactions value $
$905,205
Form type
4
Date filed
1/20/2022, 05:03 PM
Previous filing
Jan 13, 2022
Next filing
Jan 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PASG Common Stock Purchase $57.7K +10.3K +0.17% $5.60* 6.11M Jan 14, 2022 See Footnotes F1, F2, F5
transaction PASG Common Stock Purchase $626K +115K +1.88% $5.46* 6.22M Jan 18, 2022 See Footnotes F2, F3, F5
transaction PASG Common Stock Purchase $221K +43.3K +0.7% $5.11* 6.27M Jan 19, 2022 See Footnotes F2, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of the Issuer's common stock ("Shares") were purchased in a block order at price of $5.60.
F2 The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.
F3 These Shares were purchased in a block order at price of $5.46.
F4 These Shares were purchased in a block order at price of $5.11.
F5 Each of GP VII and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.